Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179

Bilal Anouti; Sandra Althouse; Greg Durm; Nasser Hanna

doi:10.1016/j.cllc.2019.06.009

Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179

Bilal Anouti, Sandra Althouse, Greg Durm, Nasser Hanna^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

We conducted a retrospective analysis of patients enrolled in the Hoosier Cancer Research Network LUN 14-179. Univariable Cox regression was performed to determine the variables associated with 3 end points: time to metastatic disease or death (TMDD), progression-free survival (PFS), and overall survival (OS). Stage IIIA and longer duration of pembrolizumab might be associated with prolonged TMDD, PFS, and OS for patients with stage III NSCLC treated with chemoradiation followed by pembrolizumab.

Original language	English (US)
Pages (from-to)	288-293
Number of pages	6
Journal	Clinical Lung Cancer
Volume	21
Issue number	3
DOIs	https://doi.org/10.1016/j.cllc.2019.06.009
State	Published - May 2020

Funding

The overall study was funded by Merck .

Keywords

Adjuvant therapy
Consolidation
Immunotherapy
Non–small-cell lung cancer
Prognosis

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cllc.2019.06.009

Fingerprint

Dive into the research topics of 'Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179'. Together they form a unique fingerprint.

Cite this

Anouti, B., Althouse, S., Durm, G., & Hanna, N. (2020). Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179. Clinical Lung Cancer, 21(3), 288-293. https://doi.org/10.1016/j.cllc.2019.06.009

@article{d19ac4ea3aea493585a60010070a7b5b,

title = "Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179",

abstract = "We conducted a retrospective analysis of patients enrolled in the Hoosier Cancer Research Network LUN 14-179. Univariable Cox regression was performed to determine the variables associated with 3 end points: time to metastatic disease or death (TMDD), progression-free survival (PFS), and overall survival (OS). Stage IIIA and longer duration of pembrolizumab might be associated with prolonged TMDD, PFS, and OS for patients with stage III NSCLC treated with chemoradiation followed by pembrolizumab.",

keywords = "Adjuvant therapy, Consolidation, Immunotherapy, Non–small-cell lung cancer, Prognosis",

author = "Bilal Anouti and Sandra Althouse and Greg Durm and Nasser Hanna",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2020",

month = may,

doi = "10.1016/j.cllc.2019.06.009",

language = "English (US)",

volume = "21",

pages = "288--293",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier Inc.",

number = "3",

}

Anouti, B, Althouse, S, Durm, G & Hanna, N 2020, 'Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179', Clinical Lung Cancer, vol. 21, no. 3, pp. 288-293. https://doi.org/10.1016/j.cllc.2019.06.009

Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179. / Anouti, Bilal; Althouse, Sandra; Durm, Greg et al.
In: Clinical Lung Cancer, Vol. 21, No. 3, 05.2020, p. 288-293.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab

T2 - A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179

AU - Anouti, Bilal

AU - Althouse, Sandra

AU - Durm, Greg

AU - Hanna, Nasser

PY - 2020/5

Y1 - 2020/5

N2 - We conducted a retrospective analysis of patients enrolled in the Hoosier Cancer Research Network LUN 14-179. Univariable Cox regression was performed to determine the variables associated with 3 end points: time to metastatic disease or death (TMDD), progression-free survival (PFS), and overall survival (OS). Stage IIIA and longer duration of pembrolizumab might be associated with prolonged TMDD, PFS, and OS for patients with stage III NSCLC treated with chemoradiation followed by pembrolizumab.

AB - We conducted a retrospective analysis of patients enrolled in the Hoosier Cancer Research Network LUN 14-179. Univariable Cox regression was performed to determine the variables associated with 3 end points: time to metastatic disease or death (TMDD), progression-free survival (PFS), and overall survival (OS). Stage IIIA and longer duration of pembrolizumab might be associated with prolonged TMDD, PFS, and OS for patients with stage III NSCLC treated with chemoradiation followed by pembrolizumab.

KW - Adjuvant therapy

KW - Consolidation

KW - Immunotherapy

KW - Non–small-cell lung cancer

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85080999941&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85080999941&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2019.06.009

DO - 10.1016/j.cllc.2019.06.009

M3 - Article

C2 - 32143966

AN - SCOPUS:85080999941

SN - 1525-7304

VL - 21

SP - 288

EP - 293

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 3

ER -

Prognostic Variables Associated With Improved Outcomes in Patients With Stage III NSCLC Treated With Chemoradiation Followed by Consolidation Pembrolizumab: A Subset Analysis of a Phase II Study From the Hoosier Cancer Research Network LUN 14-179

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this